scholarly journals Ferrous sulfate in the treatment of iron deficiency anemia: The positions continue

2017 ◽  
Vol 89 (10) ◽  
pp. 108-112
Author(s):  
L I Dvoretsky
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Dosage Form ◽  
Iron Sulfate ◽  
Deficiency Anemia ◽  
Iron Release ◽  
Comparative Efficacy ◽  
Peroxidation Processes

The paper discusses treatment strategy and tactics for iron deficiency anemia. It gives data on the comparative efficacy of different iron sulfate drugs, their bioavailability, effects on peroxidation processes, and side effects. The paper also considers the clinical significance of a dosage form of iron-containing drugs with a sustained iron release, as well as ways to reduce the frequency and magnitude of side effects when ferrous sulfate is used.

scholarly journals Lactoferrin Efficacy versus Ferrous Sulfate in Treatment of Children with Iron Deficiency Anemia

2021 ◽  
Vol 11 (01) ◽  
pp. e199-e204
Author(s):  
Osama Mahmoud El-Asheer ◽  
Ahmed Gaber Ahmed ◽  
Zainab AbdelAal Abdel Hafez ◽  
Marwa AbdelHafiz Dahpy ◽  
Amal AbdElSalam Soliman
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Patient Compliance ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Serum Iron ◽  
Deficiency Anemia ◽  
Serum Transferrin ◽  
Iron Binding ◽  
Clinical Benefits

AbstractLactoferrin (LF) is an iron-binding globular glycoprotein that is structurally and chemically similar to serum transferrin. Many studies have been done to evaluate the effect of oral LF administration on iron deficiency anemia (IDA) with controversial results. This study was designed to compare the efficacy of LF versus oral ferrous sulfate (OFS) therapy in the treatment of children with IDA. A significant increase in mean hemoglobin and serum iron concentrations was noted in the group that received oral bovine LF (11.06 ± 0.96 and 42.79 ± 6.14, respectively) versus the group that received OFS (10.24 ± 0.57 and 28.94 ± 5.05, respectively, with p < 0.001 for each) after 30 days of the treatment with fewer side effects (9.3 vs. 33.3% with p = 0.043). Oral bovine LF is a more effective and safer alternative in treating iron deficiency and IDA compared with OFS with clinical benefits of fewer side effects and better patient compliance.

A comparative study between the dispersible Ferric pyrophosphate particles and Ferrous sulfate in treatment of pediatric patients with iron deficiency anemia

2021 ◽  
Author(s):  
Fady M. El-Gendy ◽  
Ayat A El- Gendy ◽  
Mahmoud A. El-Hawy
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Complete Blood Count ◽  
Deficiency Anemia ◽  
P Value ◽  
Liquid Form ◽  
Ferric Pyrophosphate ◽  
Significant Difference

Background: Iron deficiency anemia (IDA) is the most common type of anemia related to malnutrition worldwide. It represents a major problem in developing countries, especially in Egypt. Ferric pyrophosphate (FPP) is a water-insoluble iron compound often used to fortify infant cereals and chocolate drink powders. It causes no adverse color and flavor changes to food vehicles. This study was done to compare the efficacy of FPP (micro dispersed iron) and ferrous sulfate (FS) in treating childhood IDA. Materials and Methods: This prospective cohort study was conducted on 58 anemic children visiting the outpatient clinic, pediatric department of Menoufia University hospitals from March 2017 to June 2019. The inclusion criteria of the involved children were age 2 - 12 years and the diagnosis of IDA. Patients with other types of anemia were excluded from the study. Verbal permission was obtained from the parents of the children according to the ethical committee of Menoufia University. Patients were randomly divided into 2 groups. Group1 included 29 children who were treated with FPP and group2 included 29 children who were treated with oral traditional iron in the form of FS. Complete blood count and iron profile were recorded before and after 8 weeks of treatment. Results: The results showed no statistically significant difference between the FPP group and the FS group regarding clinical examinations (P-value > 0.05). There was no significant difference regarding hemoglobin, serum iron, and serum ferritin between the FPP and the FS groups after treatment (P-value> 0.05). However, side effects were significantly higher in the FS group (P-value > 0.001). Conclusion: Micro dispersed iron could be used as an alternative therapy for children with IDA who refuse oral iron therapy in a liquid form with more tolerability and fewer side effects.

scholarly journals Assessing the Efficacy of Bovine Lactoferrin to Correct Iron Deficiency Anemia in Non-pregnant Non-lactating Women: A Randomized Controlled Trial (FS08-02-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Tanvir Huda ◽  
Michael Dibley ◽  
Shams El Arifeen ◽  
Sajia Islam ◽  
Nazia Ali ◽  
...  
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Reproductive Age ◽  
Deficiency Anemia ◽  
Bovine Lactoferrin ◽  
Women Of Reproductive Age ◽  
Lactating Women ◽  
Line P

Abstract Objectives 1. To determine if bovine lactoferrin (bLf) is at least as effective as oral ferrous sulfate in iron deficiency anemia in non-pregnant women of reproductive age (WRA) 2. To determine the optimal dose of oral bLf 3. To compare the side-effects of the treatments Methods Design: Non-inferiority, double-blind, individually RCT in non-pregnant WRA with iron deficiency anemia (Hb <12 g/dl & serum ferritin <30 μg/L) Setting: Mirpur, Dhaka, Bangladesh Participants: 555 non-pregnant, non-lactating women of 15–49 years. Interventions: Women were allocated individually (1:1:1) in three arms. Arm A, B and C received daily oral 200 mg bLf, 400 mg bLf and 60 mg ferrous sulfate. All received 400 μg of folic acid daily. Treatment was for 12 weeks. Outcomes: Serum Hb and serum ferritin at baseline and every 30 days for 3 months. Inflammatory markers: C-reactive protein (CRP); alpha(1)-Acid glycoprotein (AGP); hepcidin, at baseline and end line. Possible adverse effects were assessed. Results Women on 200 mg bLf had a decrease in Hb of 0.3 g/dl (95% CI, −0.60 to 0.00 g/dl, P = 0.05), women on 400 mg bLf arm had no change in Hb: 0.0 g/dl (95% CI, −0.32 to 0.32 g/dl, P = 1.00), and women on ferrous sulfate arm had an increase in Hb: 1.1 g/dl (95% CI, 0.83 to 1.37 g/dl, P < 0.0001). Women on 200 mg bLf had an increase in ferritin: 2.8 μg/l (95% CI, 0.38 to 5.22 μg/l, P = 0.02), women on 400 mg bLf had an increase in ferritin: 3.5 μg/l (95% CI, 0.64 to 6.36 μg/l, P = 0.02) and women on ferrous sulfate arm had an increase in ferritin: 41.1 μg/l (95% CI, 35.74 to 46.47 μg/l, P < 0.0001). There were no significant differences in AGP and CRP between arms at the base line (P = 0.38 and 0.95) and end line (P = 0.87 and 0.14). Those on ferrous sulfate had a significant increase in hepcidin concentration after 90 days (P = .000). Abdominal pain, indigestion, diarrhea and black stool were significantly higher on ferrous sulfate group. There were no differences for other side-effects across treatment arms Conclusions Ferrous sulfate has better efficacy than bLf for iron deficiency anemia in non-pregnant non-lactating women of reproductive age in urban Bangladesh. This lactoferrin product may be inactive, or there may have been inadequate dietary iron for bLF to promote its absorption. Funding Sources Saving Lives at Birth and Medical Research Council, UK.

scholarly journals IRON DEFICIENCY ANEMIA

2009 ◽  
Vol 16 (02) ◽  
pp. 209-215
Author(s):  
SHAHEEN AHMED ◽  
Salman Ali ◽  
NAEEM FAREED ◽  
Mehboob Sultan ◽  
NADEEM SADIQ ◽  
...  
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Serum Ferritin ◽  
Successful Treatment ◽  
Ferrous Sulfate ◽  
Deficiency Anemia ◽  
Control Group ◽  
Single Versus

t r o d u c t i o n : The adherence to treatment of iron deficiency anemia often is poor in both developed and developingcountries. The current standard therapy is oral ferrous sulfate administered 3 times daily. It is possible that adherence would improve witha single-dose daily treatment regimen. O b j e c t i v e s : To compare single versus thrice daily ferrous sulfate for treatment of iron deficiencyanemia in young children. D e s i g n : Quasi experimental study Setting: Children Department Military Hospital Rawalpindi. P e r i o d : From (01Jan- to31 Mar 05 and 03 Jul to 02 Oct 05) Subjects and Methods: Total 250 patients of iron deficiency anemia (hemoglobin values: 7.0to 9.9 gm/dl and serum ferritin values: 10 ng/ml or less) were identified. Children divided into two groups and matched on the basis of age;and gender. One group (n = 125) received ferrous sulfate once daily and the control group (n = 125) received ferrous sulfate thrice dailyat a total dose of 6 mg/kg/day of elemental iron for 2 months. Hemoglobin and serum ferritin values were measured as baseline and at theend of the study. R e s u l t s : Successful treatment of anemia (target hemoglobin > 10 gm/dl) occurred in 81.42 % of the single dose and in79.83 % of thrice daily dose groups and the side effects were minimal between the two groups. Conclusion: A single versus a 3 times dailydose of ferrous sulfate resulted in a similar rate of successful treatment of iron deficiency anemia, without significant side effects.

scholarly journals Ferrous sulfate liquid for the treatment of iron deficiency anemia

1981 ◽  
Vol 21 (1-2) ◽  
pp. 21
Author(s):  
Soemantri Soemantri ◽  
A. G. Soedigbia ◽  
I. Hardiman ◽  
Taty Hendarto ◽  
Widjaja Widjaja
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Vitamin C ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Deficiency Anemia ◽  
Control Group ◽  
High Dose

A study on the effect of ferrous sulfate liquid (lberet - 500 liquid) was conducted on a group of well-nourished children aged 6 months - 5 years.After 3 months 0/ treatment, hematological measurements revealed a statistically significant improvement as compared to the control group receiving placebo. Side effects were also found to be minimal. Thus ferrous sulfate liquid is recommended for treatment or supplement to anemia eradication, preferably associated with a high dose of vitamin C.

The Treatment of Iron-deficiency Anemia—Palatable but Ineffective Iron Medication

PEDIATRICS ◽  
1963 ◽  
Vol 31 (6) ◽  
pp. 1041-1044
Author(s):  
LOUIS K DIAMOND ◽  
J. LAWRENCE NAIMAN ◽  
DONALD M. ALLEN ◽  
FRANK A. OSKI,
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Oral Iron ◽  
Gastrointestinal Absorption ◽  
Deficiency Anemia ◽  
Therapeutic Effects ◽  
Rapid Rise ◽  
Carbohydrate Complex ◽  
Therapeutic Results

Experience with a new oral iron-carbohydrate complex (Jefron) in the treatment of iron-deficiency anemia shows that the therapeutic results are inferior to those obtainable with ferrous sulfate. Many children showed no response after months of treatment with this drug and when subsequently placed on ferrous sulfate therapy showed a rapid rise in hemoglobin to normal levels. Preliminary studies suggest that poor gastrointestinal absorption may be a factor in the inadequate therapeutic effects.

Iron Amino Acid Chelates

2004 ◽  
Vol 74 (6) ◽  
pp. 435-443 ◽  
Author(s):  
Hertrampf ◽  
Olivares
Keyword(s):  
Amino Acid ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Iron Absorption ◽  
Iron Status ◽  
Deficiency Anemia ◽  
Efficacy Trials ◽  
Food Matrices ◽  
The Cost

Iron amino acid chelates, such as iron glycinate chelates, have been developed to be used as food fortificants and therapeutic agents in the prevention and treatment of iron deficiency anemia. Ferrous bis-glycine chelate (FeBC), ferric tris-glycine chelate, ferric glycinate, and ferrous bis-glycinate hydrochloride are available commercially. FeBC is the most studied and used form. Iron absorption from FeBC is affected by enhancers and inhibitors of iron absorption, but to a lesser extent than ferrous sulfate. Its absorption is regulated by iron stores. FeBC is better absorbed from milk, wheat, whole maize flour, and precooked corn flour than is ferrous sulfate. Supplementation trials have demonstrated that FeBC is efficacious in treating iron deficiency anemia. Consumption of FeBC-fortified liquid milk, dairy products, wheat rolls, and multi-nutrient beverages is associated with an improvement of iron status. The main limitations to the widespread use of FeBC in national fortification programs are the cost and the potential for promoting organoleptic changes in some food matrices. Additional research is required to establish the bioavailability of FeBC in different food matrices. Other amino acid chelates should also be evaluated. Finally there is an urgent need for more rigorous efficacy trials designed to define the relative merits of amino acid chelates when compared with bioavailable iron salts such as ferrous sulfate and ferrous fumarate and to determine appropriate fortification levels

Sign in / Sign up

Export Citation Format

Share Document